| http://www.w3.org/ns/prov#value | - The new facility will manufacture dosage forms primarily in the cardiovascular, antidiabetic, anti-infective and gastrointestinal segments. ???In addition to serving the local market, the facility will also export products to markets like Asean, Mideast, Europe, Sri Lanka, China, and other select countries,??? says Arun Sawhney, CEO and managing director of Ranbaxy.
|
